Summary of Hengrui Medicine Conference Call Company Overview - **Company**: Hengrui Medicine (600276.SS) - **Industry**: Pharmaceutical, specifically focusing on innovative drug development and licensing Key Points Licensing Agreement with GSK - Hengrui has licensed out the ex-China rights of HRS-9821, a PDE3/4 inhibitor currently in phase 1 clinical trials, to GSK - The agreement includes options for the ex-China rights of up to 11 early-stage assets targeting oncology, respiratory, autoimmune, and inflammation diseases - The upfront payment for this deal is US$500 million, with potential milestone payments reaching US$12 billion based on development progress, registration, and commercialization, plus tiered royalties based on net sales [1][10] Market Potential for PDE3/4 Inhibitors - Chronic Obstructive Pulmonary Disease (COPD) affects approximately 23 million patients in the US, EU5, and Japan, with around 1.7 million patients uncontrolled on standard therapies - Currently, only three advanced treatments for COPD are approved globally, highlighting a significant unmet clinical need - Hengrui's HRS-9821 could offer advantages over existing treatments, such as a more convenient dosage form, pending further clinical data [2][9] Sales Projections - Risk-adjusted sales estimates for HRS-9821 are projected at RMB 750 million for the China market and RMB 3.2 billion for overseas markets by 2035, assuming a launch in 2030/2031 [3][12] Earnings Revision and Valuation - Earnings estimates have been revised upwards by 29% for 2025E, 0.7% for 2026E, and 0.2% for 2027E due to the licensing agreement - The 12-month price target has been adjusted to RMB 70.26 from RMB 61.74 based on these revisions and market conditions [7][12] Competitive Landscape - The PDE3/4 inhibitor market is competitive, with ensifentrine being a notable product that has achieved global sales of US$114 million in its first eight months of commercialization in 2024 - Hengrui's HRS-9821 is positioned to compete effectively, especially given its potential for broader patient coverage compared to biologic drugs [2][9] Risks and Considerations - Key risks include slower ramp-up of innovative drugs post-NRDL listing, potential failures in late-stage R&D programs, and higher-than-expected R&D expenses for global expansion - There is also a risk of greater-than-expected price cuts for generics and innovative drugs, as well as below-expected progress in licensing and global expansion [12][13] Financial Metrics - Market capitalization is approximately RMB 407 billion (US$56.7 billion) - Projected revenue growth from RMB 27.98 billion in 2024 to RMB 41.86 billion by 2027 [13] Additional Insights - The licensing deal with GSK reflects Hengrui's strategic focus on expanding its global footprint and leveraging partnerships to enhance its pipeline - The company is actively involved in the development of multiple assets, indicating a robust pipeline that could drive future growth [10][12]

Summary of Hengrui - A Conference Call Company Overview - **Company**: Hengrui Pharmaceuticals - **Industry**: Healthcare, specifically pharmaceuticals Key Points Partnership with GSK - Hengrui and GSK entered an agreement granting GSK exclusive global rights (excluding Greater China) to Hengrui's PDE3/4 inhibitor HRS-9821, currently in Phase 1 trials [2][7] - The deal includes collaborative development of up to 11 preclinical projects, with Hengrui leading R&D until Phase 1 completion [2][7] - GSK will pay Hengrui an upfront fee of **US$500 million** and potential milestone payments totaling **US$12 billion** if GSK exercises its option on the projects [2][7] Market Reaction - Following the announcement, Hengrui's H/A shares increased by **17%** and **10%**, outperforming the HSI/SHSZ300 index which saw a **0-1%** increase [2][7] - The positive market reaction indicates growing recognition of Hengrui's early pipeline assets by multinational corporations [2][7] Competitive Landscape - The deal is compared to Merck's recent acquisition of Verona, which also involved a PDE3/4 inhibitor, highlighting a trend of large pharma companies recognizing the value of Hengrui's assets [2][15] Financial Performance and Projections - Hengrui's revenue is projected to grow from **Rmb 27,985 million** in FY24 to **Rmb 35,399 million** in FY26, reflecting a year-over-year growth of **22.6%** in FY24 and **12.4%** in FY25 [9][22] - Adjusted EBITDA is expected to increase from **Rmb 7,468 million** in FY24 to **Rmb 10,393 million** in FY26, with an EBITDA margin improving from **26.7%** to **29.4%** [9][22] Valuation and Investment Thesis - Current price target for Hengrui is set at **Rmb 52.00** based on a DCF valuation, with a terminal growth rate of **4%** and a WACC of **9.3%** [10][11] - Despite strong R&D capabilities and potential for sustained growth, Hengrui's current valuation is higher than many peers, which may limit future upside [10][17] Risks - Key downside risks include potential rejection of PD-1 marketing application by the FDA and underperformance of clinical data from its ADC program [20] - Upside risks involve stronger-than-expected sales growth and earnings [20] Performance Metrics - Hengrui's market cap is approximately **$55.2 billion** with a share price of **Rmb 62.04** as of July 28, 2025 [9][10] - The company has a free float of **50.9%** and a 52-week share price range of **Rmb 62.04 - 39.62** [9][10] Conclusion - Hengrui's strategic partnership with GSK enhances its market position and validates its early-stage assets, while financial projections indicate robust growth potential. However, the company's high valuation relative to peers poses a risk to future upside, warranting a neutral rating from analysts.

FF301 致：香港交易及結算所有限公司 公司名稱: 江蘇恒瑞醫藥股份有限公司 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01276 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 258,197,600 | RMB | | 1 RMB | | 258,197,600 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 258,197,600 | RMB | | 1 RMB | | 258,197,600 | | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | ...

前十大AH股溢价率排行 智通财经APP获悉，截止8月4日收盘，东北电气(00042)、弘业期货(03678)、中石化油服(01033)分列AH 溢价率前三位，溢价率分别为831.03%、243.94%、213.16%；宁德时代(03750)、恒瑞医药(01276)、招 商银行(03968)分列AH溢价率末三位，溢价率分别为-23.53%、-6.00%、5.45%。其中安德利果汁 (02218)、金力永磁(06680)、弘业期货(03678)的偏离值位居前三，分别为31.31%、17.69%、15.76%；另 外，东北电气(00042)、中国人寿(02628)、国联民生(01456)的偏离值位居后三，分别 为-77.80%、-28.53%、-26.73%。 | 股票名称 | H股(港元) | A股 | 溢价率 | 偏离值↓ | | --- | --- | --- | --- | --- | | 安德利果汁(02218) | 18.190 | 47.25 | 211.16% | 31.31% | | 金力永磁(06680) | 18.500 | 27.01 | 74.86% | 17.69% | | 弘业期货(0 ...

Group 1 - Heng Rui Medicine (01276) experienced a rebound of over 3% in early trading, with a current stock price of 77.35 HKD and a trading volume of 254 million HKD [1] - Heng Rui has reached a cooperation agreement with GSK regarding HRS-9821 and up to 11 other projects, granting GSK exclusive licensing rights for overseas rights [1] - GSK will pay Heng Rui 500 million USD as part of the agreement, indicating significant financial backing for the projects involved [1] Group 2 - The PDE3/4 inhibitor, HRS-9821, is currently in clinical development and is considered a high-potential target for treating chronic obstructive pulmonary disease (COPD) [1] - According to Guosheng Securities, the potential of PDE3/4 inhibitors is substantial, and the business development (BD) transaction is expected to enhance Heng Rui's performance [1]

截止8月1日收盘，东北电气(00042)、弘业期货(03678)、安德利果汁(02218)分列AH溢价率前三位，溢价 率分别为800.00%、237.59%、222.93%；宁德时代(03750)、恒瑞医药(01276)、招商银行(03968)分列AH 溢价率末三位，溢价率分别为-21.81%、-0.69%、5.79%。其中安德利果汁(02218)、金力永磁(06680)、 昭衍新药(06127)的偏离值位居前三，分别为44.34%、22.81%、15.64%；另外，比亚迪股份(01211)、东 北电气(00042)、中州证券(01375)的偏离值位居后三，分别为-203.14%、-115.57%、-30.23%。 前十大AH股溢价率排行 | 股票名称 | H股(港元) | A股 | 溢价率↓ | 偏离值 | | --- | --- | --- | --- | --- | | 东北电气(00042) | 0.300 | 2.25 | 800.00% | -115.57% | | 弘业期货(03678) | 4.230 | 11.92 | 237.59% | 9.55% | | 安德利果汁(02218) | 1 ...

Core Viewpoint - The strategic partnership between Heng Rui Medicine and GlaxoSmithKline (GSK) marks a significant milestone in the internationalization of Chinese pharmaceutical companies, with a potential total deal value of up to $12 billion, reflecting a qualitative change in their position within the global pharmaceutical value chain [1][6]. Group 1: Partnership Details - Heng Rui will receive an upfront payment of $500 million from GSK, with the core project being the PDE3/4 inhibitor HRS-9821, currently in clinical development for chronic obstructive pulmonary disease (COPD) [2][3]. - The agreement allows Heng Rui to license HRS-9821 globally outside of mainland China and Hong Kong, with the potential for developing a convenient dry powder inhaler (DPI) formulation [3][4]. - The collaboration includes a scalable cooperation plan to jointly develop up to 11 additional projects, with Heng Rui leading the research and GSK retaining global development and commercialization options after Phase I trials [4][5]. Group 2: Strategic Implications - This partnership is a testament to Heng Rui's international recognition of its innovative capabilities and represents a significant step in its globalization efforts [4][5]. - For GSK, the collaboration aligns with its strategy of leveraging validated targets, allowing it to expand its research pipeline while mitigating development risks [5][6]. - The deal reflects a shift in the global pharmaceutical landscape, where Chinese companies are transitioning from being mere technology suppliers to equal partners in the global innovation network [1][6]. Group 3: Industry Transformation - The transaction highlights the evolving strategies of Chinese pharmaceutical companies, moving towards more flexible financial arrangements and performance-based payment mechanisms [6][8]. - The partnership with Hercules, where Heng Rui acquired a 19.9% stake, signifies a shift from asset sales to capital integration, creating a deeper bond between partners [7][8]. - The overall restructuring of the global pharmaceutical value chain is driven by geopolitical factors and the need for diversified global sales networks, with Chinese companies increasingly becoming rule-makers in the industry [8][9].

Performance Updates - 开拓药业-B (09939.HK) has completed patient enrollment for the Phase III clinical trial of KX-826 solution for androgenetic alopecia in adult males in China [2] - 李氏大药厂 (00950.HK) has received approval from the National Medical Products Administration for Socazolimab to be used in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer in mainland China [2] - 恒瑞医药 (01276.HK) has received approval for clinical trials of SHR-8068 injection, Adebali monoclonal antibody injection, and Bevacizumab injection [2] - 恒瑞医药 (01276.HK) has also received approval to conduct clinical trials for HRS-5041, intended for prostate cancer treatment [2] - 深圳高速公路股份 (00548.HK) reported toll revenue of 106 million yuan for the outer ring project in June [2] - 大成生化科技 (00809.HK) has signed an EPC contract with Northeast Electric and Liaoning Electric for boiler renovation projects, with a maximum cost of 129.1 million yuan [2] - 小黄鸭德盈 (02250.HK) has signed a contract to develop an AI marketing system to diversify revenue sources [2] Buyback and Financing Activities - 威海银行 (09677.HK) plans to issue up to approximately 758 million domestic shares and 154 million H-shares, raising nearly 3 billion yuan [2] Financial Results - 香港电讯-SS (06823.HK) reported total revenue of 17.322 billion HKD for the first half, a year-on-year increase of 4%, with a net profit of 2.07 billion HKD, also up 4% [4] - 青岛银行 (03866.HK) reported operating revenue of 7.662 billion yuan for the first half, a growth of 7.5%, and a net profit of 3.065 billion yuan, up 16.05% [4] - 中国石油化工股份 (00386.HK) expects mid-term net profit to be between 20.1 billion and 21.6 billion yuan, a year-on-year decline of 39.5%-43.7% [4] - 汽车之家-S (02518.HK) reported total revenue of 3.212 billion yuan for the first half, a decrease of 7.75%, with a net profit of 772 million yuan, down 15.99% [4] - 绿茶集团 (06831.HK) issued a profit warning, expecting mid-term net profit to be between 230 million and 237 million yuan, a year-on-year increase of approximately 32%-36% [4] - 粤海置地 (00124.HK) issued a profit warning, expecting mid-term net profit to exceed 260 million HKD, turning from loss to profit [4] - 药师帮 (09885.HK) issued a profit warning, expecting mid-term net profit to exceed 70 million yuan [4] - 中国东方教育 (00667.HK) issued a profit warning, expecting mid-term net profit to grow by 45%-50% year-on-year [4] - 中核国际 (02302.HK) issued a profit warning, expecting mid-term revenue to increase to at least 585 million HKD, with net profit of at least 9.5 million HKD [4] - 大唐环境 (01272.HK) issued a profit warning, expecting mid-term net profit to decrease to between 350 million and 400 million yuan [4] - 长江生命科技 (00775.HK) issued a profit warning, expecting mid-term net loss of approximately 150 million HKD, turning from profit to loss year-on-year [4] - 延长石油国际 (00346.HK) issued a profit warning, expecting mid-term loss of approximately 27.9 million HKD [4]

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS-5041, a new drug aimed at treating prostate cancer, indicating a significant advancement in its product pipeline [1] Group 1: Product Development - HRS-5041 is a novel, efficient, and selective AR-PROTAC small molecule developed by the company [1] - The drug demonstrates significant degradation effects on wild-type and various mutant AR proteins, showing potential to overcome resistance compared to second-generation AR inhibitors [1] - Currently, there are no similar products approved for market in both domestic and international markets [1] Group 2: Financial Investment - The cumulative research and development investment for the HRS-5041 project has reached approximately 69.19 million yuan [1]

Core Viewpoint - Heng Rui Medicine (01276) has received approval from the National Medical Products Administration for the clinical trial of HRS-5041, a new selective AR-PROTAC small molecule aimed at treating prostate cancer [1] Company Summary - HRS-5041 is designed to effectively degrade androgen receptor (AR) proteins, including various mutant forms, showing significant potential to overcome resistance compared to second-generation AR inhibitors [1] - The total research and development investment for the HRS-5041 project has reached approximately 69.19 million yuan [1] Industry Summary - Currently, there are no similar products approved for market release domestically or internationally, indicating a unique position for HRS-5041 in the prostate cancer treatment landscape [1]